Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MSD-001 · 1 trial · 1 indication
Treatment emergent adverse events/ treatment emergent serious adverse events - their frequency, duration and severity, clinically significant changes in lab parameters, ECG, and vital signs
| Arm | Type | Description |
|---|---|---|
| Active Treatment: MSD-001 | ACTIVE_COMPARATOR | Planned doses of MSD-001; N = 42 |
| Placebo Comparator | PLACEBO_COMPARATOR | Non-active study drug N = 10 |
| Name | Type | Description |
|---|---|---|
| MSD-001 | DRUG | MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications |
| Placebo Comparator | DRUG | Matching Placebo |
Key Inclusion Criteria: * Male or female healthy consented participants 18 to 55 years of age * CYP2D6 phenotype established based on pharmacogenetic testing. * Free from psychoactive drug use from 4 weeks before dosing and until the last follow up visit. Key Exclusion Criteria: * Any current cli...
MSD-001 is an investigational small molecule being developed for the treatment of mental health disorders. It is currently in Phase 1 clinical development and has been studied in healthy volunteers to evaluate its safety and tolerability.
MSD-001 is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker DSGN. The company is advancing this small molecule through early-stage clinical trials for mental health disorders.
MSD-001 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug is not yet approved by regulatory authorities. It remains an investigational agent under study for mental health disorders.
MSD-001 has one completed Phase 1 clinical trial, identified as NCT06702332, titled 'Single Ascending Dose Study of MSD-001 in Healthy Participants.' This randomized, double-blind, placebo-controlled study enrolled 47 healthy adults in the Netherlands.
MSD-001 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for mental health disorders. The completed Phase 1 trial assessed safety and tolerability in healthy volunteers, but the drug has not yet received regulatory approval.